Elissa Sutlief

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Host cell proteins (HCPs) must be adequately removed from recombinant therapeutics by downstream processing to ensure patient safety, product quality, and regulatory compliance. HCP process clearance is typically monitored by enzyme-linked immunosorbent assay (ELISA) using a polyclonal reagent. Recently, mass spectrometry (MS) has been used to identify(More)
  • 1